UFPT UFP Technologies

UFP Technologies Announces Record Q3 Results

UFP Technologies Announces Record Q3 Results

NEWBURYPORT, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) --   (Nasdaq: UFPT), an innovative designer and custom converter of foams, plastics, and natural fiber materials, today reported net income of $4.1 million or $0.56 per diluted common share outstanding for its third quarter ended September 30, 2018, more than double net income of $1.7 million or $0.23 per diluted common share outstanding for the same period in 2017.  Sales for the third quarter were $47.8 million, 34% higher than third quarter sales of $35.7 million in 2017.  Net income for the nine-month period ended September 30, 2018 was $9.9 million or $1.34 per diluted common share outstanding compared to $6.5 million or $0.89 per diluted common share outstanding for the same period in 2017.  Sales for the nine-month period ended September 30, 2018 were $139.8 million compared to sales of $110.6 million for the same period in 2017.

“I am very pleased with our results and continuing progress,” said R. Jeffrey Bailly, chairman and CEO. “Our legacy business grew 7.2%, driven by increased sales in our aerospace and defense, medical, and consumer markets. This organic growth, combined with revenue from our Dielectrics acquisition, enabled us to grow our overall revenue by 34%.”

“In addition, we saw significant improvements in our gross margins, driven by greater operating efficiencies and a stronger book of business,” Bailly said. “Selling, general and administrative (SG&A) expenses as a percentage of sales also decreased substantially. This combination helped us increase net income for the quarter by 144%.”

“The integration of Dielectrics is going very well,” Bailly added. “As predicted, this acquisition has been solidly accretive to UFP’s top and bottom line results. With the addition of Dielectrics’ capabilities and product lines, our value to customers and pipeline of new opportunities have never been stronger. Also, cash flow generated from our combined operations has enabled us to pay down $26 million in debt since the February 1 closing, and we continue to search for additional strategic medically-focused acquisitions. All this, combined with our strong internal growth prospects and improving operating efficiency, leaves us very bullish about our future.”

Financial Highlights

  • Organic sales (excluding sales from Dielectrics) grew 7.2% for the quarter. Aerospace and defense sales increased 44%, while consumer and medical sales grew 15% and 8%, respectively. Automotive sales declined 12% and industrial sales declined 4%.
  • Gross profit as a percentage of sales (gross margin) grew to 26%, up from 23% in the same quarter of 2017.  Material and labor collectively as a percentage of sales declined 1.4%, while overhead as a percentage of sales declined 1.6%. 
  • SG&A as a percentage of sales dropped from 16.0% to 13.7% for the third quarter vs. the prior year. Excluding SG&A at Dielectrics, the Company’s SG&A declined 1%.
  • Operating income for the quarter grew 135% to $5.9 million, from $2.5 million in the third quarter of 2017.  As a percentage of sales, operating income increased to 12.3% in the third quarter, from 7.0% in the same quarter last year.

UFP Technologies is an of foams, plastics, and natural fiber materials, principally serving the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets. The UFP team acts as an extension of its customers’ in-house research, engineering, and manufacturing groups, working closely with them to solve their most complex product and packaging challenges.

This news release contains statements relating to expected financial performance and/or future business prospects, events and plans that are forward-looking statements.  Such statements include, but are not limited to, statements regarding the Company's acquisition and integration of Dielectrics and the synergies, customer opportunities and other benefits anticipated in connection with the Dielectrics business and products, anticipated advantages the Company expects to realize from its investments and capital expenditures, anticipated revenues and the timing of such revenues, statements regarding the Company's future operating results, prospects, trends in particular markets, business opportunities, growth potential, and strategies for growth, including its acquisition strategies and other opportunities, expectations regarding the manufacturing capacity and efficiencies of the Company, and any indication that the Company may be able to sustain or increase its sales and earnings or sales and earnings growth rates.  Investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated.  Risks and uncertainties include, without limitation, risks and uncertainties associated with the Company's acquisition and integration of Dielectrics, risks associated with the effect of the acquisition of Dielectrics on the Company's earnings, risks associated with the identification of suitable ac­quisition candidates and the successful, efficient execution of acquisition transactions and integration of any acquisition candi­dates, risks relating to the Company’s ability to maintain, grow and sustain growth in new or current markets, as well as other risks and uncertainties that are detailed in the documents filed by the Company with the Securities and Exchange Commission (“SEC”).  Readers are referred to the documents filed by the Company with the SEC, specifically the last reports on Forms 10-K and 10-Q.  The forward-looking statements contained herein speak only of the Company’s expecta­tions as of the date of this press release.  The Company express­ly disclaims any obligation or undertaking to release publicly any updates or revi­sions to any such statement to reflect any change in the Company’s expectations or any change in events, conditions, or circumstances on which any such statement is based.

Consolidated Condensed Statement of Income

(in thousands, except per share data)

(unaudited)

 Three Months Ended Nine Months Ended
 September 30, September 30,
  2018   2017  2018   2017 
Net sales$  47,808  $  35,684 $  139,758  $  110,623 
Cost of sales   35,377     27,491  104,156   82,973 
Gross profit   12,431     8,193    35,602     27,650 
SG&A   6,541     5,693  20,550   18,070 
Acquisition costs   -     -  1,089     - 
Restructuring costs   -     -    -   63 
Material overcharge settlement   -     -  (104)  (121)
Loss (gain) on sale of fixed assets   5     -  (51)  3 
Operating income   5,885     2,500    14,118     9,635 
Interest (expense) income, net   (343)    51    (988)    108 
Other income   85     -  137     - 
Income before income taxes   5,627     2,551    13,267     9,743 
Income taxes   1,493     856  3,366   3,248 
Net income from consolidated operations$  4,134  $  1,695 $  9,901  $  6,495 
        
Net income per share outstanding$  0.56  $  0.23 $  1.35  $  0.90 
Net income per diluted share outstanding$  0.56  $  0.23 $  1.34  $  0.89 
        
Weighted average shares outstanding 7,366   7,264  7,338   7,240 
Weighted average diluted shares outstanding 7,435   7,353  7,406   7,326 
               

Consolidated Condensed Balance Sheets

(in thousands)

 September 30, December 31,
 2018 2017
Assets:(unaudited)  
Cash$  5,088 $  37,978
Receivables   30,144    21,381
Inventories   19,902    12,863
Other current assets   3,185    2,852
Net property, plant, and equipment   58,459    53,652
Other assets   76,982    9,481
Total assets$  193,760 $  138,207
Liabilities and equity:   
Accounts payable   7,970    4,180
Other current liabilities   10,487    5,763
Current portion of long-term debt   2,857    -
Long-term debt, excluding current portion   31,000    -
Other liabilities   5,649    4,552
Total liabilities   57,963    14,495
Total equity   135,797    123,712
Total liabilities and stockholders' equity$  193,760 $  138,207



Contact: Ron Lataille

978-234-0926,

EN
01/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UFP Technologies

 PRESS RELEASE

UFP Technologies Announces CEO Succession Plan

UFP Technologies Announces CEO Succession Plan NEWBURYPORT, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that R. Jeffrey Bailly will retire as CEO at the Company’s next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will assume the CEO position and join the Company’s Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the followin...

 PRESS RELEASE

UFP Technologies to Present and Host 1X1 Investor Meetings at the Pipe...

UFP Technologies to Present and Host 1X1 Investor Meetings at the Piper Sandler 37th Annual Healthcare Conference NEWBURYPORT, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT) a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that Chairman and Chief Executive Officer R. Jeffrey Bailly, President Mitchell C. Rock, and Chief Financial Officer Ron Lataille will participate in the upcoming Piper Sandler 37th Annual Healthcare Conference to be held in New York City December 1-4,...

UFP Technologies Inc: 1 director

A director at UFP Technologies Inc sold 1,829 shares at 227.201USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

 PRESS RELEASE

UFP Technologies Announces Strong Q3 2025 Results

UFP Technologies Announces Strong Q3 2025 Results NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter were $154.6 million compared to ...

 PRESS RELEASE

UFP Technologies to Report Third Quarter 2025 Financial Results on Nov...

UFP Technologies to Report Third Quarter 2025 Financial Results on November 3, 2025 Conference Call Scheduled for November 4th at 8:30 AM ET NEWBURYPORT, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that the Company plans to report results for the third quarter on Monday, November 3rd, after the close of the stock market. The Company will hold a conference call to discuss the results on the following day, November 4th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch